Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

500 patients join study to unravel recurrent heart inflammation

NCT ID NCT04687358

Knowledge-focused Sponsor: Kiniksa Pharmaceuticals International, plc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 500 children and adults with recurrent pericarditis (repeated inflammation of the heart lining) to better understand the disease. Researchers will track which treatments patients use, how the disease affects quality of life, and the economic costs. The goal is to improve care and support future treatment recommendations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2021

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with active or inactive recurrent pericarditis who have participated in the RHAPSODY (KPL-914-C002) Phase 3 clinical study of rilonacept and patients from sites who have expressed an interest in the registry will be included. In addition, RESONANCE will also include decentralized sites for remote patients who wish to participate in the registry but are not near a registry site.

Ages

7 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

ACTIVE RP PATIENTS Select Inclusion Criteria: * Physician-confirmed (or confirmation in medical records) diagnosis of RP defined as an initial, acute, episode and at least one pericarditis recurrence after the initial acute episode * Experienced at least one pericarditis episode in the 3 years prior to inclusion * Under the care of a physician for the treatment and management of RP * Currently prescribed medication for RP Select Exclusion Criteria: * Diagnosis of pericarditis secondary to tuberculosis (TB), cancer if not in full remission, post thoracic blunt trauma (e.g., motor-vehicle accidents), myocarditis, systemic autoimmune diseases, except SJIA and adult Still's disease, HIV * Appears to have an impairment (e.g., cognitive, hearing, visual) or insufficient English or Spanish proficiency that could interfere with ability to complete patient-completed assessments * Currently enrolled in a therapeutic investigational drug or device study INACTIVE RP PATIENTS Select Inclusion Criteria: * Physician-confirmed (or confirmation in medical records) diagnosis of RP defined as an initial, acute, episode and at least one pericarditis recurrence after the initial, acute episode * Patient had a last episode occurring at least 3 years and up to 5 years before registry inclusion * Resolution of RP symptoms confirmed with no further RP treatment for 3 years prior to registry enrollment Select Exclusion Criteria: * Experienced a pericarditis episode within 3 years from enrolling in the registry * Currently receiving RP treatment prescribed by a treating physician (e.g., CS, colchicine) * Diagnosis of pericarditis secondary to tuberculosis (TB), cancer if not in full remission, post thoracic blunt trauma (e.g., motor-vehicle accidents), myocarditis, systemic autoimmune diseases except SJIA and adult Still's disease, HIV * Enrolled in a therapeutic investigational clinical trial during the observation period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent pericarditis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic recurrent pericarditis pericarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent pericarditis

Contacts and locations

Locations

  • Alaska Heart & Vascular Institute

    Anchorage, Alaska, 99508, United States

  • Barnes-Jewish Hospital/Washington University

    St Louis, Missouri, 63110, United States

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Carnegie Mellon University, Allegheny Health Network, Allegheny General Hospital

    Pittsburgh, Pennsylvania, 15212, United States

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44106, United States

  • Detroit Medical Center

    Detroit, Michigan, 48201, United States

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21218, United States

  • Legacy Medical Group, Cardiology

    Portland, Oregon, 97227, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic - PPDS

    Rochester, Minnesota, 55905, United States

  • Midwest Cardiovascular Research Foundation

    Davenport, Iowa, 52801, United States

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota, 55407, United States

  • NYU Langone Health

    New York, New York, 10016, United States

  • Northwell Health - Lenox Hill Hospital

    New York, New York, 10075, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Pima Heart and Vascular

    Tucson, Arizona, 85718, United States

  • Scripps Health

    San Diego, California, 92037, United States

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

  • Swedish Medical Center - Cherry Hill

    Seattle, Washington, 98122, United States

  • TKL Research Inc.

    Fair Lawn, New Jersey, 07410, United States

  • The Linder Research Center at The Christ Hospital

    Cincinnati, Ohio, 45219, United States

  • University of California San Diego Medical Center

    La Jolla, California, 92093, United States

  • University of Nebraska

    Omaha, Nebraska, 68198, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Utah

    Salt Lake City, Utah, 84132, United States

  • University of Vermont Medical Center

    Burlington, Vermont, 05405, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.